Myomo, Inc. (MYO)
USD 4.38
(2.46%)
USD 4.38
(2.46%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 21.41 Million USD | 2.34% |
| 2022 | 20.92 Million USD | 1.68% |
| 2021 | 20.58 Million USD | 32.9% |
| 2020 | 15.48 Million USD | 12.91% |
| 2019 | 13.71 Million USD | 12.01% |
| 2018 | 12.24 Million USD | 61.07% |
| 2017 | 7.6 Million USD | 85.58% |
| 2016 | 4.09 Million USD | 2.95% |
| 2015 | 3.97 Million USD | 15.56% |
| 2014 | 3.44 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 6.18 Million USD | 11.73% |
| 2024 Q2 | 6.44 Million USD | 4.08% |
| 2023 FY | 21.41 Million USD | 2.34% |
| 2023 Q3 | 5.51 Million USD | 2.4% |
| 2023 Q1 | 4.97 Million USD | 2.5% |
| 2023 Q4 | 5.53 Million USD | 0.45% |
| 2023 Q2 | 5.38 Million USD | 8.14% |
| 2022 Q2 | 5.29 Million USD | -0.36% |
| 2022 Q1 | 5.31 Million USD | -8.79% |
| 2022 FY | 20.92 Million USD | 1.68% |
| 2022 Q4 | 4.85 Million USD | -10.97% |
| 2022 Q3 | 5.45 Million USD | 3.0% |
| 2021 Q4 | 5.82 Million USD | 9.88% |
| 2021 Q2 | 4.8 Million USD | 3.37% |
| 2021 Q1 | 4.64 Million USD | 3.95% |
| 2021 FY | 20.58 Million USD | 32.9% |
| 2021 Q3 | 5.3 Million USD | 10.45% |
| 2020 FY | 15.48 Million USD | 12.91% |
| 2020 Q2 | 3.28 Million USD | -20.03% |
| 2020 Q3 | 3.61 Million USD | 9.98% |
| 2020 Q4 | 4.46 Million USD | 23.58% |
| 2020 Q1 | 4.11 Million USD | 8.06% |
| 2019 Q4 | 3.8 Million USD | 17.54% |
| 2019 FY | 13.71 Million USD | 12.01% |
| 2019 Q3 | 3.23 Million USD | -2.96% |
| 2019 Q2 | 3.33 Million USD | -0.02% |
| 2019 Q1 | 3.33 Million USD | -1.82% |
| 2018 Q1 | 2.6 Million USD | 20.77% |
| 2018 Q4 | 3.39 Million USD | 8.79% |
| 2018 FY | 12.24 Million USD | 61.07% |
| 2018 Q2 | 3.11 Million USD | 19.4% |
| 2018 Q3 | 3.12 Million USD | 0.32% |
| 2017 Q2 | 2.14 Million USD | 42.64% |
| 2017 Q1 | 1.5 Million USD | 3.59% |
| 2017 Q3 | 1.79 Million USD | -15.97% |
| 2017 Q4 | 2.15 Million USD | 20.01% |
| 2017 FY | 7.6 Million USD | 85.58% |
| 2016 Q4 | 1.44 Million USD | 39.23% |
| 2016 Q2 | 892.46 Thousand USD | 24.65% |
| 2016 Q3 | 1.04 Million USD | 16.64% |
| 2016 Q1 | 715.97 Thousand USD | -23.86% |
| 2016 FY | 4.09 Million USD | 2.95% |
| 2015 FY | 3.97 Million USD | 15.56% |
| 2015 Q1 | 1.04 Million USD | 0.0% |
| 2015 Q4 | 940.3 Thousand USD | 0.0% |
| 2015 Q3 | 940.3 Thousand USD | -10.37% |
| 2015 Q2 | 1.04 Million USD | -0.0% |
| 2014 FY | 3.44 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Abbott Laboratories | 15.71 Billion USD | 99.864% |
| Allurion Technologies Inc. | 120.57 Million USD | 82.24% |
| Artivion, Inc. | 223.43 Million USD | 90.416% |
| Avanos Medical, Inc. | 375.5 Million USD | 94.297% |
| Butterfly Network, Inc. | 162.46 Million USD | 86.819% |
| Butterfly Network, Inc. | 162.46 Million USD | 86.819% |
| Bio-Rad Laboratories, Inc. | 1.04 Billion USD | 97.956% |
| Boston Scientific Corporation | 7.47 Billion USD | 99.714% |
| CONMED Corporation | 564.24 Million USD | 96.205% |
| Edwards Lifesciences Corporation | 3.09 Billion USD | 99.307% |
| Paragon 28, Inc. | 210.1 Million USD | 89.808% |
| Glaukos Corporation | 367.83 Million USD | 94.178% |
| Globus Medical, Inc. | 887.16 Million USD | 97.586% |
| Inspire Medical Systems, Inc. | 568.49 Million USD | 96.233% |
| Integer Holdings Corporation | 250.95 Million USD | 91.467% |
| Medtronic plc | 16.12 Billion USD | 99.867% |
| Nevro Corp. | 389.36 Million USD | 94.5% |
| Owlet, Inc. | 51.21 Million USD | 58.191% |
| Penumbra, Inc. | 590.87 Million USD | 96.376% |
| Vicarious Surgical Inc. | 80.66 Million USD | 73.454% |
| Smith & Nephew plc | 3.46 Billion USD | 99.382% |
| Sonendo, Inc. | 68.46 Million USD | 68.723% |
| STERIS plc | 1.4 Billion USD | 98.471% |
| Stryker Corporation | 9.2 Billion USD | 99.767% |
| Vapotherm, Inc. | 66.02 Million USD | 67.567% |
| Zimmer Biomet Holdings, Inc. | 3.27 Billion USD | 99.346% |